Biotech stocks sold off in 2022. The papers from Mainz Biomed also flew out of many depots. But in the meantime the title has bottomed out and could now take off again.
Cancer: high mortality, high costs!
More than 50,000 people die each year from colon cancer in the US alone. However, if this is detected early, the probability of survival increases to up to 90 percent in the first five years. If the tumor has already progressed too far, not even a fifth of those affected will survive in this period. Accordingly, preventive medical check-ups are important. So far, colonoscopies have been the method of choice. But they are expensive, time-consuming and many people find the treatment extremely uncomfortable.
Innovative procedure for colorectal cancer detection
Mainz Biomed (6.60 euros | NL0015000LC2) has developed a diagnostic procedure that combines two approaches. With the product ColoAlert, the stool is examined for blood from the tumor. But that only helps if the tumors also give off blood. In addition, specific biomarkers are used that recognize the tumor DNA in the stool. The process is considered highly effective and has already been approved in Europe. In addition, ColoAlert can be easily ordered online and carried out at home. The analysis is then carried out in conventional laboratories using the PCR tests known from the pandemic. With a cost of around 200 euros, the test is currently not affordable for everyone.
Mainz Biomed: Sales in focus, USA in mind!
Accordingly, sales are the focus for the management around CEO Guido Baechler. ColoAlert is available through the company’s online store or through physicians. In addition, Mainz Biomed has entered into partnerships with large laboratory chains that sell the colorectal cancer test via their respective networks. …
Read the full article…
